New combo therapy aims to slow advanced breast cancer in patients who relapsed
NCT ID NCT06849947
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a combination of two drugs (fulvestrant and ribociclib) works better than standard treatments for people with a certain type of advanced breast cancer (HR+, HER2-). The cancer has returned after the patient finished a prior course of CDK4/6 inhibitors. About 272 adults will take part, and the main goal is to see how long the cancer stays under control.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER, METASTATIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a drug cocktail cure metastatic breast cancer? a trial aims to find out
- PET scan could reveal which breast cancer patients will respond to targeted therapy
- New study aims to catch lymphedema early in breast cancer patients
- Mapping the hidden toll: how breast cancer brain metastases affect daily life
- New decision tool aims to ease tough talks for advanced breast cancer patients
- Zapping just a few spots: new hope for patients with worsening metastatic cancer?